Biochip technology reveals fingerprints of biochemical threats

prepared under various conditions, which can be used to identify an unknown sample from a possible terrorist attack,” Schabacker said. “This will be a major help to investigators who seek to attributing the agent to a particular perpetrator.” Schabacker plans to leverage basic studies on the anthrax bacterium from the laboratory of Loyola professor Adam Driks to make biochips into a powerful tool for investigators and other scientists.

Developed in the early part of the decade originally as a diagnostic tool, a biochip consists of a one-centimeter by one-centimeter array that contains anywhere between several dozen and several hundred “dots,” or small drops. Each of these drops contains a unique protein, antibody or nucleic acid that will attach to a particular reagent.

Scientists obtain the anthrax proteins to create the biochip through a process called fractionation. Essentially, the scientists use chemicals to break open the anthrax bacterium and collect its cellular proteins. They then use another process to separate the individual proteins by their physiochemical properties.

This process creates hundreds of separate protein fractions, which are then deposited onto a single biochip. Scientists then use different chemicals, or reagents, to characterize the resulting biochips just as a detective would dust for fingerprints. Just like a police interview with a suspect, this chemical process is known as “interrogation.” When a reagent interacts with a particular protein fraction, a spot will “light up,” creating part of the protein signature.

Although the biochip technology has the potential to develop protein signatures of just about any biological agent, Schabacker and Driks have devoted their initial focus initially to B. anthracis. The spores produced by this bacterium, which cause anthrax, are relatively easily manufactured and dispersed, making the anthrax bacterium a relatively easily produced biological weapon.

B. anthracis is a pretty forgiving species — it will grow in a bunch of different conditions,” Schabacker said. “It’s probably the single most attractive pathogen of choice to terrorists who don’t have a lot of really expensive equipment or expertise, and the spores are the perfect package for dispersion.”

An expert on anthrax, Driks and his laboratory pioneered the forensic analysis of the spore coat of the bacterium. Schabacker combined the biochip technology with fractionation technology developed by Eprogen, Inc., providing a nexus that connects government research, academia and industry.

Helping scientists track down terrorists is not the biochip’s only use. Biochips have already shown promise in diagnostic medicine. After developing the biochip technology, Schabacker licensed it to several companies, including Safeguard Biosciences in Toronto, Canada and Akonni Biosystems in Frederick, Maryland. Instead of looking at anthrax, Eprogen has put biochips to use to look for common cancer biomarkers. That research could open the door for doctors to create “antibody profiles” that could help them design individualized drugs or treatment programs for patients.

The work Akonni has done focuses on identifying other pathogens — those not normally associated with terrorist activity. Soon, biochips may begin showing up in greater numbers in doctor’s offices around the country, as they provide accurate and speedy diagnoses of a wide variety of infections, such as those caused by Multidrug-Resistant Tuberculosis (MDR-TB) and the often deadly Methicillin-resistant Staphylococcus aureus aureus (MRSA).

Argonne National Laboratory seeks solutions to pressing national problems in science and technology. The U.S. first national laboratory, Argonne conducts leading-edge basic and applied scientific research in virtually every scientific discipline. Argonne researchers work closely with researchers from hundreds of companies, universities, and federal, state and municipal agencies to help them solve their specific problems, advance America ‘s scientific leadership and prepare the nation for a better future. With employees from more than 60 nations, Argonne is managed by UChicago Argonne, LLC for the U.S. Department of Energy’s Office of Science.